Literature DB >> 7530234

Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer.

J Dillner1, F Wiklund, P Lenner, C Eklund, V Frederiksson-Shanazarian, J T Schiller, M Hibma, G Hallmans, U Stendahl.   

Abstract

In a seroepidemiological study of incident cervical cancer, 94 cases and 188 population-based controls were used to evaluate the disease-association of IgG and IgA antibody responses against 6 human papillomavirus (HPV) type-16 antigens. Nine of the tested antibody responses were positively associated with cervical cancer, with odds ratios (ORs) ranging from 2.5 to 15.0. The antibody responses most strongly associated with cervical cancer were IgA against E6:10, an epitope derived from the carboxyterminal part of the HPV16 E6 [OR = 15.0, confidence intervals (CI) = 5.9-48.6], IgG against HPV16 virus-like particles (OR = 9.5, CI = 3.9-28.0) and IgG against the E1:19 epitope in the middle part of the E1 protein of HPV16 (OR = 7.7, C1 = 3.9-16.5). When the 3 serological assays that showed the strongest association with cervical cancer were combined, positivity for 2 assays was found among 52% of cases at an OR of 29.9. We conclude that antibody responses to several linear and conformational HPV epitopes are independently associated with cervical cancer and that combined analysis of several HPV antibody responses can result in better predictive values for HPV-associated cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7530234     DOI: 10.1002/ijc.2910600318

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer.

Authors:  W Meschede; K Zumbach; J Braspenning; M Scheffner; L Benitez-Bribiesca; J Luande; L Gissmann; M Pawlita
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

Review 2.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

3.  Interlaboratory agreement among results of human papillomavirus type 16 enzyme-linked immunosorbent assays.

Authors:  H D Strickler; A Hildesheim; R P Viscidi; K V Shah; B Goebel; J Drummond; D Waters; Y Sun; N L Hubbert; S Wacholder; L A Brinton; C L Han; P C Nasca; R McClimens; K Turk; V Devairakkam; S Leitman; C Martin; J T Schiller
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

4.  Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study.

Authors:  M Lehtinen; J Dillner; P Knekt; T Luostarinen; A Aromaa; R Kirnbauer; P Koskela; J Paavonen; R Peto; J T Schiller; M Hakama
Journal:  BMJ       Date:  1996-03-02

5.  Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women.

Authors:  R P Viscidi; K L Kotloff; B Clayman; K Russ; S Shapiro; K V Shah
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

6.  HPV-16 E2 gene disruption and sequence variation in CIN 3 lesions and invasive squamous cell carcinomas of the cervix: relation to numerical chromosome abnormalities.

Authors:  D A Graham; C S Herrington
Journal:  Mol Pathol       Date:  2000-08

7.  Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination.

Authors:  M Kibur; V af Geijerstamm; E Pukkala; P Koskela; T Luostarinen; J Paavonen; J Schiller; Z Wang; J Dillner; M Lehtinen
Journal:  Sex Transm Infect       Date:  2000-02       Impact factor: 3.519

8.  Prevalence and risk factors for neutralizing antibodies to human papillomavirus types 16 and 18 in HIV-positive men who have sex with men.

Authors:  Rachna Sharma; Jimmy T Efird; Aung Chein; Elizabeth A Holly; Mel Krajden; J Michael Berry; Teresa M Darragh; Naomi Jay; Joel M Palefsky
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-15       Impact factor: 3.731

9.  Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments.

Authors:  T Yamada; C M Wheeler; A L Halpern; A C Stewart; A Hildesheim; S A Jenison
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

10.  Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer.

Authors:  K S Anderson; J Wong; G D'Souza; A B Riemer; J Lorch; R Haddad; S I Pai; J Longtine; M McClean; J LaBaer; K T Kelsey; M Posner
Journal:  Br J Cancer       Date:  2011-06-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.